Guillem Argilés

7.2k total citations · 1 hit paper
95 papers, 2.5k citations indexed

About

Guillem Argilés is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Guillem Argilés has authored 95 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 22 papers in Cancer Research. Recurrent topics in Guillem Argilés's work include Colorectal Cancer Treatments and Studies (57 papers), Cancer Treatment and Pharmacology (28 papers) and Cancer Genomics and Diagnostics (20 papers). Guillem Argilés is often cited by papers focused on Colorectal Cancer Treatments and Studies (57 papers), Cancer Treatment and Pharmacology (28 papers) and Cancer Genomics and Diagnostics (20 papers). Guillem Argilés collaborates with scholars based in Spain, United States and France. Guillem Argilés's co-authors include Josep Tabernero, Élena Elez, Takayuki Yoshino, Dirk Arnold, Ramón Salazar, Julien Taı̈eb, Timothy Iveson, Daniel Hochhauser, Pierre Laurent‐Puig and Erika Martinelli and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Guillem Argilés

91 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2020 736 citations Guillem Argilés, Josep Tabernero et al. Annals of Oncology profile →

Peers

Guillem Argilés

ONCOL

PFM

PRM

Fortunato Ciardiello Italy

Philip J. Gold United States

Romain Cohen France

Alessio Amatu Italy

Katia Bencardino Italy

Cristiana Lupi Italy

Yuan‐Tzu Lan Taiwan

Ki Y. Chung United States

Syma Iqbal United States

Fortunato Ciardiello Italy

Guillem Argilés

1.7k ×0.9

ONCOL

435 ×0.6

537 ×0.9

PFM

697 ×1.2

PRM

456 ×1.1

Citations per year, relative to Guillem Argilés Guillem Argilés (= 1×) peers Fortunato Ciardiello

Countries citing papers authored by Guillem Argilés

Since Specialization

Citations

This map shows the geographic impact of Guillem Argilés's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guillem Argilés with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guillem Argilés more than expected).

Fields of papers citing papers by Guillem Argilés

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guillem Argilés. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guillem Argilés. The network helps show where Guillem Argilés may publish in the future.

Co-authorship network of co-authors of Guillem Argilés

This figure shows the co-authorship network connecting the top 25 collaborators of Guillem Argilés. A scholar is included among the top collaborators of Guillem Argilés based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guillem Argilés. Guillem Argilés is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Johannet, Paul, Henry Walch, Benoı̂t Rousseau, et al.. (2024). Molecular and Clinicopathologic Impact of GNAS Variants Across Solid Tumors. Journal of Clinical Oncology. 42(32). 3847–3857. 5 indexed citations

Lenz, Heinz‐Josef, Guillem Argilés, Maja J.A. de Jonge, et al.. (2024). A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors. ESMO Open. 9(11). 103729–103729. 5 indexed citations

Foote, Michael B., James R. White, Walid K. Chatila, et al.. (2024). Analysis of Shared Variants between Cancer Biospecimens. Clinical Cancer Research. 31(2). 376–386.

Foote, Michael B., Guillem Argilés, Benoı̂t Rousseau, & Neil H. Segal. (2023). Facts and Hopes in Colorectal Cancer Immunotherapy. Clinical Cancer Research. 29(20). 4032–4039. 5 indexed citations

Cutsem, Eric Van, Iwona Danielewicz, Mark Saunders, et al.. (2022). First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study. British Journal of Cancer. 126(11). 1548–1554. 9 indexed citations

Bordonaro, Roberto, Aitana Calvo, A. Auriemma, et al.. (2021). Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study. ESMO Open. 6(5). 100270–100270. 11 indexed citations

Argilés, Guillem, Josep Tabernero, Roberto Labianca, et al.. (2020). Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 31(10). 1291–1305. 736 indexed citations breakdown →

Lenz, Heinz‐Josef, Guillem Argilés, Takayuki Yoshino, et al.. (2019). Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses. Clinical Colorectal Cancer. 18(4). 269–279.e5. 6 indexed citations

Argilés, Guillem, Manuel Valladares‐Ayerbes, Cristina Grávalos, et al.. (2019). Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC). Annals of Oncology. 30. iv135–iv135. 15 indexed citations

10.

Argilés, Guillem, Thierry André, Antoine Hollebecque, et al.. (2019). Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer. European Journal of Cancer. 112. 12–19. 8 indexed citations

11.

Mattos‐Arruda, Leticia De, Carmen Criscitiello, Matteo Lambertini, & Guillem Argilés. (2018). ESMO Leaders Generation Programme: an alumni insight. ESMO Open. 3(1). e000312–e000312. 1 indexed citations

12.

Argilés, Guillem. (2018). Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer. ESMO Open. 3(4). e000377–e000377. 1 indexed citations

13.

García-Ruiz, Alonso, Juan Martín-Liberal, Cinta Hierro, et al.. (2018). Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability. Annals of Oncology. 29. viii653–viii653. 5 indexed citations

14.

Cutsem, Eric Van, Takayuki Yoshino, Heinz‐Josef Lenz, et al.. (2018). Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. Annals of Oncology. 29(9). 1955–1963. 49 indexed citations

15.

Azuara, Daniel, Cristina Santos, Adriana López‐Doriga, et al.. (2016). Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies. Molecular Cancer Therapeutics. 15(5). 1106–1112. 12 indexed citations

16.

Dienstmann, Rodrigo, Amita Patnaik, Rocio García‐Carbonero, et al.. (2015). Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discovery. 5(6). 598–609. 58 indexed citations

17.

Arqués, Oriol, Irene Chicote, Isabel Puig, et al.. (2015). Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clinical Cancer Research. 22(3). 644–656. 147 indexed citations

18.

Gupta, Shilpa, Guillem Argilés, Pamela N. Münster, et al.. (2015). A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. Clinical Cancer Research. 21(23). 5235–5244. 27 indexed citations

19.

Sanz‐García, Enrique, et al.. (2015). Current and advancing treatments for metastatic colorectal cancer. Expert Opinion on Biological Therapy. 16(1). 93–110. 31 indexed citations

20.

Gupta, Supriya, Antoine Hollebecque, Guillem Argilés, et al.. (2014). Safety and Efficacy of MK-8669 (Ridaforolimus) + MK-2206 (AKT Inhibitor) in Patients with Advanced Breast Cancer with PI3K Pathway Dependence. Annals of Oncology. 25. i25–i25. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact